** Cancer therapy developer Kronos Bio's shares rise 4% to 90 cents premarket
** KRON to lay off about 83% of its employees by year-end
** CEO Norbert Bischofberger has stepped down after nearly six years in the role - KRON
** KRON appoints chief financial officer Deborah Knobelman as interim CEO
** As of March 11, KRON had 62 full-time employees and one part-time employee - SEC filing
** KRON had announced ~21% reduction in its workforce earlier this year
** As of last close, stock has fallen ~31% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.